Description: Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing products for bone marrow/hematopoietic stem cell BM/HSC transplant market, including CDX bi-specific antibody and CAR-T therapy for eliminating relapsed and/or refractory acute myeloid leukaemia, acute lymphoblastic leukaemia, and myelodysplastic syndrome; and Human Postnatal Hemogenic Endothelial Cells, a cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.
Home Page: www.hemogenyx.com
HEMO Technical Analysis
60 Gracechurch Street
London,
EC3V 0HR
United Kingdom
Phone:
44 79 0917 7311
Officers
| Name | Title |
|---|---|
| Dr. Vladislav Sandler Ph.D. | Co-Founder, CEO & Director |
| Ms. Alexis M. Sandler J.D. | Independent Co-Founder & Non-Exec. Director |
| Mr. Andrew Wright | Financial Controller & Company Sec. |
| Dr. Koen Van Besien M.D., Ph.D. | Clinical Advisor & Medical Director |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.806 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |